68
Participants
Start Date
June 12, 2023
Primary Completion Date
October 1, 2025
Study Completion Date
March 1, 2026
Adagrasib
Adagrasib is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.
Instiute Jules Bordet, Brussels
Centre Hospitalier d'Avignon, Avignon
Caen - CHU, Caen
Le Mans - CHG, Le Mans
Hôpital de Marseille, Marseille
Beaumont Hospital, Dublin
St James's Hospital, Dublin
University Hospital Limerick, Limerick
University Hospital Waterford, Waterford
Fondazione IRCCS Policlinico S. Matteo, Pavia
Santa Maria della Misericordia Hospital, Perugia
"Istituto Nazionale Tumori Regina Elena", Rome
AULSS2 Marca Trevigiana Treviso, Treviso
Complejo Hospitalario Universitario a Coruña, A Coruña
Alicante University Hospital, Alicante
ICO Badalona - Hospital Germans Trias i Pujol, Badalona
Hospital de Basurto, Bilbao
ICO Bellvitge -H. Duran i Reynals / H. Bellvitge, L'Hospitalet de Llobregat
Hospital Universitario Fundacion Jimenez Diaz, Madrid
Hospital Universitario Puerta de Hierro, Madrid
Hospital General Universitario de Valencia (University Hospital Valencia), Valencia
Christie NHS Manchester, Manchester
Collaborators (1)
Mirati Therapeutics Inc.
INDUSTRY
ETOP IBCSG Partners Foundation
NETWORK